Top story

Corcept Receives Complete Response Letter for Relacorilant as a Treatment for Patients with Hypercortisolism

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Dec. 31, 2025-- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and...

Read full story

Pfizer and BioNTech’s Comirnaty Receives U.S. FDA Approval for Adults 65 and Older and Individuals Ages 5 through 64 at Increased Risk for Severe COVID-19

Drugs.com - New Drug Approvals

Wed, 27 Aug 2025

Gadoquatrane New Drug Application Accepted for Review by U.S. FDA

Drugs.com - New Drug Applications

Wed, 27 Aug 2025

US FDA Approves New Biktarvy Indication For People With HIV Who Are Treatment Experienced And Restarting Antiretroviral Treatment

Drugs.com - New Drug Approvals

Wed, 30 Jul 2025

FDA Approves Anzupgo (delgocitinib) Cream for the Treatment of Chronic Hand Eczema

Drugs.com - New Drug Approvals

Wed, 23 Jul 2025

FDA Approves Khindivi (hydrocortisone) Oral Solution for Pediatric Patients with Adrenocortical Insufficiency

Drugs.com - New Drug Approvals

Wed, 28 May 2025

FDA Approves Tryptyr (acoltremon) Ophthalmic Solution for the Treatment of Dry Eye Disease

Drugs.com - New Drug Approvals

Wed, 28 May 2025

Otsuka Announces FDA Acceptance and Priority Review of Biologics License Application (BLA) for Sibeprenlimab in the Treatment of Immunoglobulin A Nephropathy (IgAN)

Drugs.com - New Drug Applications

Tue, 27 May 2025

FDA Extends PDUFA Date of Biohaven's Troriluzole NDA for Rare Disease Spinocerebellar Ataxia

Drugs.com - New Drug Applications

Wed, 14 May 2025

FDA Approves Atzumi (dihydroergotamine) Nasal Powder for the Acute Treatment of Migraine

Drugs.com - New Drug Approvals

Wed, 30 Apr 2025